TITLE

Funding for HIV network extended

PUB. DATE
June 1997
SOURCE
CMAJ: Canadian Medical Association Journal;06/01/97, Vol. 156 Issue 11, p1524
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the extension of the federal government's stable funding for the Canadian HIV Trials Network (CTN). Research projects of the organization; National director of the group.
ACCESSION #
9706123933

 

Related Articles

  • Hundreds enrolled in Canadian HIV trials.  // CMAJ: Canadian Medical Association Journal;06/15/97, Vol. 156 Issue 12, p1691 

    Reports on the Canadian volunteers enrolled in a protease inhibitor study that is the first large-scale collaborative clinical trial involving the Canadian HIV Trials Network (CTN) and American researchers. Comparison of the effectiveness of a 2-drug combinations with AZT against the highest...

  • A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-noninfected... Perry, R.T.; Plowe, C.V.; Koumaré, B.; Bougoudogo, F.; Kotloff, K.L.; Losonsky, G.A.; Wasserman, S.S.; Levine, M.M. // Bulletin of the World Health Organization;1998, Vol. 76 Issue 1, p63 

    Provides information on randomized clinical trials conducted in Mali on adults who are infected with the Human Immunodeficiency Virus (HIV), with focus on the use of a single dose of live oral cholera vaccine. Details on the seventh cholera pandemic caused by Vibrio cholerae; Methodology used...

  • New drugs to fight resistant HIV near market.  // Indianapolis Business Journal;10/04/99, Vol. 20 Issue 29, p21 

    Focuses on the impending market introduction of drugs to fight HIV infections after the final findings of clinical trials. Drug companies with the new drug developments; Gene-testing technology used for the drugs.

  • Microbicide Research Will Prevail Despite Most Recent Setback, Experts Say.  // AIDS Alert;Jul2007, Vol. 22 Issue 7, Special section p1 

    The article focuses on the impact of the cancellation of a phase III clinical trial studying cellulose sulfate to block HIV infection on microbicide research in the U.S.

  • One STEP forward, two steps back.  // AIDS Alert;Jun2008, Vol. 23 Issue 6, p68 

    The article reports that the STEP trial, a scientific concept tested in the HIV vaccine, did not produce the desired beneficial effect, according to Anthony S. Fauci, director at the National Institute of Allergy and Infectious Diseases National Institutes of Health (NIAID).

  • Microbicide candidate found safe, but not effective -- What's the next step in research? Bowers, Rebecca // Contraceptive Technology Update;May2008 Supplement, Vol. 29, p1 

    The article reports that the first effectiveness trial for a microbicide indicate that while Carraguard is safe to use, it is not effective in the prevention of male-to-female HIV transmission.

  • HIV trials instructive to other researchers.  // AIDS Alert;Sep2009, Vol. 24 Issue 9, p103 

    The article reports on the effort of HIV investigators and research sponsors to develop new ways to educate communities about HIV clinical trials in the U.S.

  • The Quest Trial, a paradigm of HIV collaborative research. Goh, Li-Ean; McDade, Hugh; Kinloch, Sabine; Perrin, Luc; Cooper, David; Phillips, Andrew; Hoen, Bruno; Autran, Brigitte; Sonnerborg, Anders; Tsoukas, Chris // Nature Medicine;Nov2000, Vol. 6 Issue 11, p1194 

    Presents an example of a clinical trial involving multi-party collaboration. GlaxoWellcome's initiation of an international study to assess whether highly active anti-retroviral therapy administered to patients with HIV-1 would allow for long-term control of viral replication whe treatment was...

  • Scientific and Ethical Considerations in Trial Design for Investigational Agents for the Treatment of Human Immunodeficiency Virus Infection. Feinberg, Judith; Japour, Anthony J. // Clinical Infectious Diseases;1/15/2003, Vol. 36 Issue 2, p201 

    The design of clinical trials for new antiretroviral agents poses unique challenges, given the availability of highly active antiretroviral therapy (HAART). These challenges include the selection of appropriate populations, the methods used to partition the effects of the study drug under...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics